Replimune to resubmit twice-rejected drug for approval after FDA shakeup
RSS SUMMARY · AGGREGATED FROM CNBC
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
US
Amazon engineers in Seattle slam employer for building AI data centers while laying off 30,000 staffers
CNBC·5h ago·3 min read
US
Elon Musk’s net worth poised to sail past $1 trillion in SpaceX IPO
CNBC·6h ago·3 min read
US
Broadcom stock slips on disappointing software revenue
CNBC·8h ago·3 min read
US
Senate GOP strips up to $1B for Trump ballroom security from immigration enforcement bill
CNBC·9h ago·3 min read
Related
On this beat
Business
Flesh-Eating Screwworm Found in Texas Calf, USDA Says
TWSJ·1h ago·3 min read
Business
Slumping Chinese oil imports ‘shield’ global market from higher prices
FT·1h ago·3 min read
Business
Flesh-Eating Pest Confirmed in U.S. Cattle
TNYT·2h ago·3 min read
Business
Pace Gallery Cuts 50 Artists and 50 Staff Amid Art Market Challenges
TNYT·2h ago·3 min read